Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma, progress to full-blown cancer. With further validation, these findings could revolutionize how these patients are diagnosed and treated.
Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions https://t.co/qjV1Hlek3y Who will progress to active disease myeloma? Who won’t?
— Jim Omel (@IMFjimMYELOMA) March 26, 2021